Related Experiment Video
Updated: Jul 14, 2026
06:46
Quantitative Micro-CT Analysis of Aortopathy in a Mouse Model of β-aminopropionitrile-induced Aortic Aneurysm and Dissection
Published on: July 16, 2018
Inhibited aortic aneurysm formation in BLT1-deficient mice
Neil Ahluwalia1, Alexander Y Lin, Andrew M Tager
1Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA 02129, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|June 21, 2007
Summary
Leukotriene B(4) receptor BLT1 is crucial for abdominal aortic aneurysm (AAA) formation in mice. Blocking BLT1 reduces AAA incidence and size by inhibiting inflammation and matrix-degrading enzymes.
Area of Science:
- Vascular Biology
- Immunology
- Pharmacology
Background:
- Leukotriene B(4) (LTB4) is a potent inflammatory mediator.
- The LTB4 receptor, BLT1, is expressed on leukocytes and implicated in vascular diseases.
- Abdominal aortic aneurysm (AAA) is a serious complication of atherosclerosis.
Purpose of the Study:
- To investigate the role of BLT1 in the development of abdominal aortic aneurysms (AAA).
- To determine if BLT1 deficiency protects against AAA formation in a murine model.
Main Methods:
- Utilized a murine model of AAA using Apoe(-/-) and Apoe(-/-)/Blt1(-/-) mice.
- Administered angiotensin II infusion to induce AAA formation.
- Assessed AAA incidence, size, leukocyte infiltration, and matrix metalloproteinase (MMP) levels.
Main Results:
- BLT1-deficient mice (Apoe(-/-)/Blt1(-/-)) exhibited significantly reduced AAA formation compared to controls (Apoe(-/-)).
- AAA size (diameter and area) was significantly smaller in BLT1-deficient mice.
- Reduced leukocyte accumulation and lower levels of MMP-2 and MMP-9 were observed in BLT1-deficient mice.
Conclusions:
- BLT1 plays a critical role in promoting AAA formation in this murine model.
- BLT1 deficiency attenuates AAA development by reducing inflammation and inhibiting key enzymes like MMPs.
- Targeting BLT1 may offer a therapeutic strategy for preventing or treating AAA and other atherosclerotic vascular diseases.
